Acquisition, Expansion, Diversification: Myriad Looks to Evolve Beyond Cancer Diagnostics
May 04, 2011
Acquisition, Expansion, Diversification: Myriad Looks to Evolve Beyond Cancer Diagnostics
Myriad has acquired Rules-Based Medicine, taken steps to establish a European presence, and bolstered its companion diagnostics capabilities in an attempt to squelch negative Wall Street perceptions that it's a one-product company.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Reporting 27 Percent Q3 Jump, Myriad Outlines Three-Pronged Plan for Diversifying Revenue Base
May 2, 2012 / Pharmacogenomics Reporter - Myriad Reports 20 Percent Q1 Revenue Growth, Rising Demand for Colorectal Cancer Test
November 2, 2011 / Pharmacogenomics Reporter - Securing Crescendo Option, Myriad Continues to Seek Avenues for Growing Beyond Oncology Diagnostics
September 14, 2011 / Pharmacogenomics Reporter - Myriad Highlights RBM Pharma Work, Reports $2M in Q4 Revenues from Companion Diagnostics
August 12, 2011 / ProteoMonitor - Posting 11 Percent Revenue Growth in FY2011, Myriad Focuses on Growing MDx Pipeline
August 10, 2011 / Pharmacogenomics Reporter